Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Florida’s home insurance market is experiencing a wave of optimism as recent litigation reforms lead to fewer lawsuits, stronger insurer stability, and even rate reductions. With companies like Florida Peninsula lowering premiums and 17 new insurers entering the state, real estate, mortgage, and insurance professionals can expect smoother transactions, increased buyer confidence, and a more competitive market environment in the year ahead.
Mortgage rates have dipped to levels not seen since 2022, with the 30‑year fixed averaging just 6.361% and Freddie Mac reporting an even lower 6.06%. The drop is reshaping buyer affordability, sparking renewed market activity, and creating fresh opportunities for real estate professionals—especially in fast‑moving markets like Florida.
The 2026 housing market is shaping up to be one of the most pivotal in years, with mortgage rates showing slight relief, affordability shifting toward the Midwest and South, and buyers turning to options like ARMs and new‑construction homes. Early signals point to new opportunities for buyers, investors, and real‑estate professionals—especially those ready to navigate a market defined by moderate rate drops, regional affordability gaps, and builder‑driven incentives.
Ares Commercial Real Estate CEO Bryan Donohoe sold US$107k in shares this week, trimming his stake by 13% and adding to a pattern of insider selling with no insider purchases in the past 12 months. With insider ownership sitting at a modest 1.6%, the activity signals a cautious tone inside the company—something real estate, mortgage, and finance professionals may want to watch as they assess broader market confidence.
Florida’s 2026 legislative session is officially underway, launching a wave of high‑impact bills targeting property insurance reform, a proposal to eliminate property taxes, new education attendance requirements, and even an AI Bill of Rights. With over a hundred bills already filed, real estate agents, investors, insurers, educators, and other licensed professionals can expect significant regulatory shifts that may reshape Florida’s housing market, insurance costs, and professional compliance standards.
Warren Buffett’s timeless investing wisdom is more relevant than ever in 2026. Despite decades of market change, his core lesson remains the same: long‑term conviction outperforms short‑term prediction. From embracing occasional underperformance to avoiding emotional decisions, Buffett’s philosophy highlights why deep understanding and steady confidence are more valuable than trying to forecast market swings. This mindset isn’t just for investors—it’s a guiding principle for professionals looking to grow their careers with clarity and purpose.
